$36.38
2.16% yesterday
Nasdaq, Nov 25, 10:00 pm CET
ISIN
US30161Q1040
Symbol
EXEL

Exelixis, Inc. Stock price

$36.38
+8.51 30.53% 1M
+15.81 76.86% 6M
+12.39 51.65% YTD
+14.77 68.35% 1Y
+18.90 108.12% 3Y
+19.60 116.81% 5Y
+34.66 2,015.12% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
+0.77 2.16%
ISIN
US30161Q1040
Symbol
EXEL
Sector
Industry

Key metrics

Market capitalization $10.39b
Enterprise Value $9.39b
P/E (TTM) P/E ratio 23.18
EV/FCF (TTM) EV/FCF 21.71
EV/Sales (TTM) EV/Sales 4.51
P/S ratio (TTM) P/S ratio 4.99
P/B ratio (TTM) P/B ratio 4.57
Revenue growth (TTM) Revenue growth 17.31%
Revenue (TTM) Revenue $2.08b
EBIT (operating result TTM) EBIT $608.28m
Free Cash Flow (TTM) Free Cash Flow $432.69m
Cash position $1.19b
EPS (TTM) EPS $1.57
P/E forward 21.96
P/S forward 4.82
EV/Sales forward 4.36
Short interest 4.30%
Show more

Is Exelixis, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Exelixis, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

23 Analysts have issued a Exelixis, Inc. forecast:

14x Buy
61%
7x Hold
30%
2x Sell
9%

Analyst Opinions

23 Analysts have issued a Exelixis, Inc. forecast:

Buy
61%
Hold
30%
Sell
9%

Financial data from Exelixis, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
2,082 2,082
17% 17%
100%
- Direct Costs 78 78
17% 17%
4%
2,004 2,004
17% 17%
96%
- Selling and Administrative Expenses 462 462
5% 5%
22%
- Research and Development Expense 906 906
20% 20%
44%
636 636
635% 635%
31%
- Depreciation and Amortization 28 28
39% 39%
1%
EBIT (Operating Income) EBIT 608 608
1,383% 1,383%
29%
Net Profit 467 467
407% 407%
22%

In millions USD.

Don't miss a Thing! We will send you all news about Exelixis, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Exelixis, Inc. Stock News

Neutral
Investors Business Daily
4 days ago
The top five biotech stocks today have several commonalities. Among them are strong ratings.
Positive
The Motley Fool
23 days ago
The price could be right for these stocks.
Positive
Seeking Alpha
26 days ago
Exelixis's Cabometyx continues to drive revenue growth, prompting a raised 2024 forecast to $2.15–$2.2 billion. EXEL plans to diversify its oncology portfolio by launching one new indication for Zanzalintinib annually. Zanzalintinib could also grow into a $5 billion yearly revenue asset by 2033, potentially surpassing Cabometyx as Exelixis's primary revenue source. The company has repurchased $...
More Exelixis, Inc. News

Company Profile

Exelixis, Inc. is a biopharmaceutical company, which engages in the development, commercialization, and discovery of new medicines for the treatment of cancer. It offers products under the brands of Cometriq, Cabometyx, and Cotellic. The company was founded by Corey S. Goodman and Stelios B. Papadopoulos on November 15, 1994 and is headquartered in Alameda, CA.

Head office United States
CEO Michael Morrissey
Employees 1,310
Founded 1994
Website www.exelixis.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today